Clinical trial
Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With…
NCT04233918 · Regeneron Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT04233918 |
|---|---|
| Title | Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia |
| Official title | A Three-Part, Single-Arm, Open-Label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia |
| Lead sponsor | Regeneron Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Homozygous Familial Hypercholesterolemia |
| Intervention type | Drug |
| Interventions | Evinacumab |
| Enrollment | 20 |
| Start date | Jun 29, 2020 |
| Primary completion | Jan 31, 2022 |
| Completion | May 30, 2023 |
| First posted | Jan 18, 2020 |
| Last update posted | Jul 16, 2024 |
| Countries | Australia, Austria, Netherlands, Taiwan, Ukraine, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: